Patent details

301093 Product Name: Baloxavir marboxil, alsmede farmaceutisch aanvaardbare zouten en solvaten ervan

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301093
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2620436
Status:
Application Pending
Application number:
301093
Procedural language:
Dutch
First Applicant Residence Country:
Japan (JP)

Marketing Authorization

Marketing Authorization Number:
EU/1/20/1500
Marketing Authorization Type:
EEA
Marketing Authorization Date:
08/01/2021
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
02/03/2021
First Marketing Authorization date:
08/01/2021
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
02/03/2021
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
02/03/2021
 
 

 

Name:
Shionogi & Co. Ltd.
Address:
1-8 Doshomachi 3-chome, Chuo-ku, Osaka-shi, 5410045, Osaka, Japan (JP)

Agent

Name:
ir. M.F.J.M. Ketelaars c.s.
From:
02/03/2021
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

Bulletin Heading:
SPC
Journal edition number:
09/21
Publication date:
03/03/2021
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
03/06/2024 SPC Documents Accompanying letter SPC 13 PDF /5/3/9/5/5/0800655935/docs/301093_12_supplprotectioncertificate20240604095245752.pdf
09/04/2024 Outgoing Correspondence Letter to applicant 1 PDF /5/3/9/5/5/0800655935/docs/301093_9_599971l173.pdf
08/04/2024 Incoming Correspondence Electronic Accompanying letter incoming document 1 PDF /5/3/9/5/5/0800655935/docs/301093_10_incomingcorrespondenceelectronic20240408021152672.pdf
10/01/2024 Outgoing Correspondence Letter to applicant 6 PDF /5/3/9/5/5/0800655935/docs/301093_11_585576l173.pdf
09/03/2021 Incoming Correspondence Paper Accompanying letter incoming document 1 PDF /5/3/9/5/5/0800655935/docs/301093_5_incomingcorrespondencepaper20210310123330717.pdf
02/03/2021 Outgoing Correspondence Confirmation receipt request 1 PDF /5/3/9/5/5/0800655935/docs/301093_0_397581l174.pdf
02/03/2021 SPC Documents Annex SPC 14 PDF /5/3/9/5/5/0800655935/docs/301093_1_supplprotectioncertificate20210302102352885.pdf
02/03/2021 SPC Documents Marketing Authorization SPC 3 PDF /5/3/9/5/5/0800655935/docs/301093_2_supplprotectioncertificate20210302102015757.pdf
02/03/2021 SPC Documents Annex SPC 2 PDF /5/3/9/5/5/0800655935/docs/301093_3_supplprotectioncertificate20210302102329105.pdf
02/03/2021 Application Form First filed application form 2 PDF /5/3/9/5/5/0800655935/docs/301093_4_applicationform20210302101459803.pdf
02/03/2021 SPC Documents Annex SPC 10 PDF /5/3/9/5/5/0800655935/docs/301093_6_supplprotectioncertificate20210302102520455.pdf
02/03/2021 SPC Documents Accompanying letter SPC 3 PDF /5/3/9/5/5/0800655935/docs/301093_7_supplprotectioncertificate20210302101926035.pdf
02/03/2021 SPC Documents Summary of the characteristics of the product 13 PDF /5/3/9/5/5/0800655935/docs/301093_8_supplprotectioncertificate20210302102307961.pdf